Last reviewed: October 2026 · Cleared Peptides research team
Research use only. UBT-251: Research Guide to the GLP-1/GIP/Glucagon Triple Agonist is supplied for laboratory research. It is not a drug, food, cosmetic, or dietary supplement. It is not FDA-approved. It is not for human or veterinary administration. This page does not give a dose or a method of administration. A study cited on this page describes that study’s own test article. It does not make this lot an approved medicine. To check a fact, open the PubMed or DOI link, confirm the authors and year, and match the paper’s compound name, CAS number, or sequence to the specification table. The full method is on the research desk page. Identity and purity for a lot are only what that lot’s certificate of analysis reports. An HPLC percentage is not a sterility result and not an endotoxin result unless the certificate prints those tests.
UBT-251 (UBT251) is an investigational synthetic peptide described as a triple agonist at the GLP-1, GIP and glucagon receptors — the same receptor profile as retatrutide. Public structural detail is limited, so identity is confirmed per lot on the COA.
UBT-251 Structure and Identifiers
| Name | UBT-251 |
|---|---|
| Code | UBT251 |
| Class | Synthetic peptide; GLP-1R/GIPR/GCGR triple agonist (investigational) |
| CAS number | Not available. No public CAS Registry Number was found in the sources reviewed for this guide. |
| Identity | Confirmed per lot COA |
| Form | Lyophilized powder |
Triple Agonists in Research
Unimolecular triple agonists let researchers study combined activation of GLP-1, GIP and glucagon receptors in one ligand. UBT-251 provides a second triple-agonist chemotype for comparison with retatrutide in receptor-selectivity and cAMP assays.
Comparison
| Compound | Receptors (described) | CAS |
|---|---|---|
| Retatrutide | GIPR + GLP-1R + GCGR | 2381089-83-2 |
| UBT-251 | GIPR + GLP-1R + GCGR | Not publicly listed |
| Tirzepatide | GIPR + GLP-1R | 2023788-19-2 |
This summary describes laboratory research only and makes no claim about effects in humans or animals.
Purity Testing and Storage
Every lot of UBT-251 supplied by Cleared Peptides is tested by an independent laboratory for identity and purity (or composition, for multi-component preparations), and the lot Certificate of Analysis is published on our COA page. Store lyophilized UBT-251 at −20 °C, sealed, dry and protected from light. Allow the vial to reach room temperature before opening and minimize freeze–thaw cycles. Handle according to your institution’s chemical-hygiene procedures.
Research materials referenced in this guide
Analytical testing notes for UBT-251
UBT-251 is identified in this guide as CAS Not available. No public CAS Registry Number was found in the sources reviewed for this guide.. An identity test compares a measurement with those values. A mass spectrum is the usual measurement for a peptide. FTIR, when a certificate uses it, is a supporting infrared fingerprint and is less specific for closely related sequences.
UBT-251 carries a fatty-acid or other lipophilic modification, so it is among the later-eluting peptides on a C18 column. Laboratories often raise the acetonitrile fraction, the column temperature, or move to a C8 or C4 column so the main peak is sharp enough to integrate. The mass used for identity has to include the lipid chain and linker, not only the amino-acid backbone. Area-percent purity still ignores water and counterion.
HPLC purity for this material is an area-percent result at the wavelength and gradient the laboratory states, commonly ultraviolet detection near 214 nm on a reversed-phase column. The instrument is a gradient pump, injector, column oven, and UV or diode-array detector. That percentage is not the number of milligrams in the vial. Water, acetate, trifluoroacetate, and other UV-silent material can dominate the gross weight while the purity figure stays high. Net peptide content, from an assay or amino-acid analysis, is the separate result to read when the certificate reports it.
A sterility test and an endotoxin test are not included in a chemical purity result. The compendial sterility test is a culture method (USP <71>): membrane filtration or direct inoculation into fluid thioglycollate medium and soybean-casein digest medium, incubated for 14 days. A PCR sterility screen uses a thermal cycler to detect microbial DNA and is a different method. The endotoxin test (USP <85> LAL, or USP <86> recombinant Factor C) reports endotoxin units with an incubating reader or a cartridge reader. Use a result only when that method is printed on the lot certificate. One published example in this catalog states that the report does not cover microbial contamination or endotoxins. The full description of equipment, standards, and how US laboratory accreditation works is in peptide analytical testing. Lot records are on the COA page.
Frequently Asked Questions
How does UBT-251 compare with retatrutide?
Both are described as GLP-1/GIP/glucagon triple agonists; they are distinct molecules useful for side-by-side receptor studies.
Is UBT-251 for human use?
No. Cleared Peptides supplies UBT-251 for laboratory research use only; it is not for human or veterinary use.
Selected References
A public CAS Registry Number and a peer-reviewed PubMed record that defines a formula and sequence for UBT-251 were not identified when this guide was reviewed. Identity for each lot is the batch COA.
Laboratory note: solubility depends on salt form and solvent. This guide does not state a single solubility figure. Handling of lyophilized material is described in the peptide storage guide.
Research Use Only Notice
This guide is provided for educational and laboratory reference purposes. It summarizes published, primarily in-vitro and structural research literature and does not describe, recommend or imply any use in humans or animals. Products sold by Cleared Peptides are for laboratory research use only; they are not drugs, foods, cosmetics or dietary supplements, are not FDA-approved, and are not intended to diagnose, treat, cure, mitigate or prevent any disease. No dosing, administration or therapeutic information is provided.
